PH12021551975A1 - Use of vibegron to treat overactive bladder - Google Patents

Use of vibegron to treat overactive bladder

Info

Publication number
PH12021551975A1
PH12021551975A1 PH1/2021/551975A PH12021551975A PH12021551975A1 PH 12021551975 A1 PH12021551975 A1 PH 12021551975A1 PH 12021551975 A PH12021551975 A PH 12021551975A PH 12021551975 A1 PH12021551975 A1 PH 12021551975A1
Authority
PH
Philippines
Prior art keywords
vibegron
overactive bladder
treat overactive
treat
directed
Prior art date
Application number
PH1/2021/551975A
Other languages
English (en)
Inventor
Jr Paul N Mudd
Original Assignee
Urovant Sciences Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Urovant Sciences Gmbh filed Critical Urovant Sciences Gmbh
Publication of PH12021551975A1 publication Critical patent/PH12021551975A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PH1/2021/551975A 2019-03-18 2020-03-18 Use of vibegron to treat overactive bladder PH12021551975A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962820230P 2019-03-18 2019-03-18
US201962830302P 2019-04-05 2019-04-05
US201962842435P 2019-05-02 2019-05-02
US201962885767P 2019-08-12 2019-08-12
US201962897019P 2019-09-06 2019-09-06
US201962904429P 2019-09-23 2019-09-23
PCT/IB2020/052484 WO2020188505A1 (en) 2019-03-18 2020-03-18 Use of vibegron to treat overactive bladder

Publications (1)

Publication Number Publication Date
PH12021551975A1 true PH12021551975A1 (en) 2022-07-04

Family

ID=70166082

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2021/551975A PH12021551975A1 (en) 2019-03-18 2020-03-18 Use of vibegron to treat overactive bladder

Country Status (14)

Country Link
US (1) US20230027066A1 (cg-RX-API-DMAC7.html)
EP (2) EP4763281A2 (cg-RX-API-DMAC7.html)
JP (2) JP2022524576A (cg-RX-API-DMAC7.html)
KR (2) KR20260049872A (cg-RX-API-DMAC7.html)
CN (2) CN121489955A (cg-RX-API-DMAC7.html)
AU (2) AU2020243514A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021017198A2 (cg-RX-API-DMAC7.html)
CA (1) CA3129024A1 (cg-RX-API-DMAC7.html)
IL (1) IL285910A (cg-RX-API-DMAC7.html)
MX (1) MX2021009488A (cg-RX-API-DMAC7.html)
PH (1) PH12021551975A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202108810YA (cg-RX-API-DMAC7.html)
TW (2) TW202506129A (cg-RX-API-DMAC7.html)
WO (1) WO2020188505A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250099259A (ko) 2017-06-06 2025-07-01 유로반트 사이언시즈 게엠베하 과민성 방광의 치료를 위한 비베그론의 용도
TW202038963A (zh) 2018-12-05 2020-11-01 瑞士商優洛凡特科學公司 維貝隆(vibegron)於治療患有良性前列腺增生之男性中膀胱過動症症狀之用途
TW202245781A (zh) * 2021-02-16 2022-12-01 瑞士商優洛凡特科學公司 用維貝格龍(vibegron)治療心臟衰竭之方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20091825A1 (es) 2008-04-04 2009-12-04 Merck & Co Inc Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3
ES2584427T3 (es) 2011-10-27 2016-09-27 Merck Sharp & Dohme Corp. Proceso para la preparación de agonistas beta 3 y productos intermedios
WO2013062881A1 (en) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Process for making beta 3 agonists and intermediates
JP6383403B2 (ja) 2013-03-15 2018-08-29 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. β−3作動薬および中間体の製造方法
JP6197971B1 (ja) * 2016-04-22 2017-09-20 小野薬品工業株式会社 Kcnq2〜5チャネル関連疾患の予防および/または治療剤
WO2017210696A1 (en) * 2016-06-03 2017-12-07 Velicept Therapeutics, Inc. Dosing regimens for beta-3 adrenoceptor agonists and anti-muscarinic agents for the treatment and prevention of lower urinary tract symptoms and overactive bladder
US10057209B2 (en) * 2016-07-28 2018-08-21 Qualcomm Incorporated Time-sequenced multi-device address assignment
KR20250099259A (ko) * 2017-06-06 2025-07-01 유로반트 사이언시즈 게엠베하 과민성 방광의 치료를 위한 비베그론의 용도
CN110869053A (zh) * 2017-06-06 2020-03-06 乌洛万特科学有限公司 给药维贝隆以治疗膀胱过度活动症
EP3583905A1 (en) * 2018-06-20 2019-12-25 Arthrex Inc Percutaneous targeting device

Also Published As

Publication number Publication date
TW202102221A (zh) 2021-01-16
AU2025256180A1 (en) 2025-11-13
JP2022524576A (ja) 2022-05-09
US20230027066A1 (en) 2023-01-26
KR20260049872A (ko) 2026-04-14
BR112021017198A2 (pt) 2021-11-16
EP3941473A1 (en) 2022-01-26
EP4763281A2 (en) 2026-06-24
WO2020188505A1 (en) 2020-09-24
IL285910A (en) 2021-10-31
AU2020243514A1 (en) 2021-08-26
SG11202108810YA (en) 2021-10-28
CA3129024A1 (en) 2020-09-24
CN121489955A (zh) 2026-02-10
CN113840607A (zh) 2021-12-24
MX2021009488A (es) 2021-09-21
KR20210142004A (ko) 2021-11-23
TW202506129A (zh) 2025-02-16
JP2025084777A (ja) 2025-06-03

Similar Documents

Publication Publication Date Title
MX2020011653A (es) Métodos de tratamiento para el abuso de sustancias.
ZA202202361B (en) Treatment of hidradenitis suppurativa using jak inhibitors
PH12019500845A1 (en) Combinations comprising an ssao/vap-1 inhibitor and a sglt2 inhibitor, uses thereof
MX2018012165A (es) Metodos de tratamiento de canceres pediatricos.
AU2018282105A1 (en) Dosing of vibegron for treatment of overactive bladder
MX2019013279A (es) Metodos de tratamiento del sindrome de doose utilizando fenfluramina.
EP4424367A3 (en) Treatment of hair loss disorders with deuterated jak inhibitors
SG10201810401RA (en) Pharmaceutical combinations for treating cancer
ZA202000028B (en) Use of vibegron to treat overactive bladder
EP4324454A3 (en) Cross-linking agents and associated methods
ZA202006072B (en) Ret inhibitor for use in treating cancer having a ret alteration
WO2023081830A3 (en) Compositions and treatments with nirogacestat
MX2021001264A (es) Métodos para tratar la vejiga hiperactiva con el uso de trospio.
MX2022007113A (es) Inhibidores de la desmetilasa de la histona especifica de la lisina para el tratamiento de las neoplasias mieloproliferativas.
MX2024000701A (es) Metodos de tratamiento de la enfermedad de alzheimer.
MX2022012632A (es) Uso de inhibidores del bromodominio para el tratamiento de la enfermedad de huntington.
BR112021017198A2 (pt) Uso de vibegron para tratar bexiga hiperativa
PH12021550741A1 (en) Vibegron for the treatment of overactive bladder symptoms
MX2021002754A (es) Tratamiento del autismo y trastornos dentro del espectro del autismo con composiciones de biotina.
MX2020007817A (es) Prevención y tratamiento del trastorno del sueño.
EA201992414A1 (ru) Комбинация nk1-антагониста и способ лечения синуклеинопатий
EA202193276A1 (ru) Способы лечения холангиокарциномы
MX2021002590A (es) Metodos de uso de un compuesto de fenoxipropilamina para tratar el dolor.
WO2020005869A3 (en) Compositions and methods for the treatment of cancer characterized with pcsk9 expression
CL2021003303A1 (es) Tratamiento para sinucleinopatías.